$PVCT News Article - Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10 and KEYTRUDA for Checkpoint-Na ve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020
https://marketwirenews.com/news-releases/prov...58650.html